Modern conceptions of an uric acid role in development of essential hypertension


Cite item

Full Text

Abstract

The article deals with current studies on the role of uric acid (UA) in development of cardiovascular diseases. The results of large prospective trials are presented which have revealed a pathogenetic role of UA in development of essential hypertension. Clinical trials demonstrated elevated concentrations of UA in hypertensive patients. Experimental evidence suggests UA involvement in the processes of nonspecific inflammation, oxidant stress, endothelial dysfunction. It is shown that elevated UA levels in blood serum lead to affection of target organs.

About the authors

Ol'ga Vasil'evna Polovitkina

Elena Vladimirovna Oshchepkova

Viktor Aleksandrovich Dmitriev

Email: vicdmi@mail.ru

Vladimir Nikolaevich Titov

O V Polovitkina

Russian Research Cardiological Center, Moscow

Russian Research Cardiological Center, Moscow

E V Oschepkova

Russian Research Cardiological Center, Moscow

Russian Research Cardiological Center, Moscow

V A Dmitriev

Russian Research Cardiological Center, Moscow

Russian Research Cardiological Center, Moscow

V N Titov

Russian Research Cardiological Center, Moscow

Russian Research Cardiological Center, Moscow

References

  1. Pillinger M. H., Rosenthal P. Hyperuricaemia and gout: new insights into pathogenesis and treatment. Bull. N. Y. Univ. Hosp. Jt. Dis. 2007; 66 (3): 215-221.
  2. Mahomed F. A. On chronic bright's disease and its essential symptoms. Lancet 1879; 1: 399-401.
  3. Huchard H. Allgemiene Betrachtungen uber die Arteriosklerose. Klin. Med. 1909; 5: 1318-1321.
  4. Duffy W. B., Senekjian H. O., Knight T. F., Weinman E. J. Management of asymptomatic hyperuricemia. J. A. M. A. 1981; 246: 2215-2216.
  5. Nakagava T., Tuttle K. R., Short R. A. et al. Fructose-induced hyperuricemia as a casual mechanism for the epidemic of the metabolic syndrome. Nat. Clin. Рract. Nephrol. 2005; 1: 80- 86.
  6. Niskanen L. K., Laaksonen D. E., Nyyssönen K. et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-age men: a prospective cohort study. Arch. Intern. Med. 2004; 164: 1546-1551.
  7. Verdechia P., Schilaci G., Reboldi G. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072- 1078.
  8. Band F. N., McGee D. L., Kennel W. B. Hyperuricemia as a risk factor of coronary heart disease: the Framinghem Heart Study. Am. J. Epidemiol. 1985; 121 (1): 11-18.
  9. Fang J., Alderman M. N. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic Follow-up study 1971-1992. National health and nutrition examination survey. J. A. M. A. 2000; 238 (18): 2404-2410.
  10. Alper A. B., Chen W., Yau L. et al. Childhood uric acid predicts adulthood blood pressure: The Bogalusa Heart Study. Hypertension 2005; 45: 33-38.
  11. Perlstein T. S., Guminiak O. Uric acid and the development of hypertension: The Normative Aging Study. Hypertension 2006; 48: 1031-1036.
  12. Sundstrom J., Sullivan L. Relation of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
  13. Lurbe E., Torres C., Torro I. et al. Uric acid and cardiovascular risk factors in adolescent. In: 19th European meeting on hypertension, Milan, June 12-16, 2009: Milan; 2009. P. 9. 242; S 104.
  14. Faig D. L., Johnson R. J. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247-252.
  15. Krishnan E., Kent Kwoh C., Schumacher H. R. et al. Hyperuricemia and Incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
  16. Feig D. I., Soletsky B., Johnson R. J. Effect on blood pressure of adolescents with new diagnosed essential hypertension: a randomized trial. J. A. M. A. 2008; 300 (8): 924-932.
  17. Viazzi F, Parodi D, Leoncini G. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996.
  18. Ощепкова E. B., Дмитриев B. A., Половиткина О. В., Титов В. Н. Содержание мочевой кислоты и ее роль на ранних стадиях гипертонической болезни. Систем. гипертенз. 2009; 2: 51-54.
  19. Nemirska A., Sladovska J., Antoniewicz J. et al. Uric acid concentration, metabolic syndrome components and target organ damage in adolescents and adults with essential hypertension. In: European meeting on hypertension, Milan, June 15-19, 2007. Milan; 2007. P37. 193; S346-S347.
  20. Hermida R. C., Chayan L., Ayala D. E. et al. Association of metabolic syndrome and blood pressure nondipping profile in untreated hypertension. Am. J. Hypertens. 2009; 22 (3): 307- 313.
  21. Afsar B., Elsurer R., Ozdemir F. N. et al. Uric acid and nocturnal nondiping in hypertensive patients with normal renal function. J. Nephrol. 2008; 21 (3): 406-411.
  22. Forman J. P., Choi H., Curhan G. C. Plasma uric acid level and risk for incident hypertension among men. J. Am. Soc. Nephrol. 2007; 18: 287-292.
  23. Mazzali M., Hughes J., Yoon-Goo Kim et al. Elevated uric acid increases blood pressure in the rats by a novel Crystal - Independent mechanism. Hypertension 2001; 38: 1101-1106.
  24. Sanches-Lozada L. G., Tapia E., Avia-Casado C. et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am. J. Physiol. Renal Physiol. 2002; 283: F1105-F1110.
  25. Watanabe S., Kang D. H., Feng L. et al. Uric acid, hominoid evolution and the pathogenesis salt-sensivity. Hypertension 2002; 40: 355-360.
  26. Nakagawa T., Mazzali M., Duk-Hee Kang et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am. J. Nephrol. 2003; 23: 2-7.
  27. Bellomo G., Berardi P., Saronio P. et al. Microalbuminuria and uric acid in healthy subjects. J,. Nephrol. 2006; 19: 458-464.
  28. Jung Eun Lee, Yoon-Goo Kim, Choi Y. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006;47: 962-967.
  29. Viazzi F., Parodi D., Leoncini G. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996.
  30. Мухин Н. А., Балкаров И. М., Шоничев Д. Г. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Тер. арх. 1999; 6: 23- 27.
  31. Мухин Н. А., Моисеев В. С., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.
  32. Serban С., Susan L., Pacurari A. et al. Association between serum uric acid levels and atherosclerosis in hypertensive patients. In: 19th European meeting on hypertension, Milan, June 12-16, 2009. Milan; 2009. P 23. 218; S 249.
  33. Zoccali C., Maio R., Mallamaci F. et al. Uric acid and endothelial dysfunction in essential hypertension. J. Аm. Soс. Nephrol. 2006; 17: 1466-1471.
  34. Khosla U. M., Zharikov S., Finch J. L. et al. Hyperuricemia induces endothelial dysfunction. Kidney 2005; 67 (5): 1739- 1742.
  35. Corry D. B., Eslami P., Yamamoto K. et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angioterisin system. J. Hypertens. 2008; 26: 269-275.
  36. Rao G. N., Corson M. A., Berk В. С. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J. Biol. Chem. 1991; 266: 8604-8608.
  37. Netea M. G., Rullberg B. J., Blok W. L. et al. The role of Hyperuricemia in the increased cytokine production after lipopolisaccharide challenge in neutropenic mice. Blood. 1997; 89: 577-582.
  38. Mazzali M., Kanellis J., Han L., Feng L. Hyperuricemia induces a primarily renal arteriolopathy in rats by a blood pressure -independent mechanism. Am. J. Physiol. Renal Physiol. 2002; 289: 991-997.
  39. Kanellis J., Watanabe S., Jin H. Li et al. Uric acid stimulates monocyte chemoattractant rpotein-1 production in vascular smooth muscle cells via mitogen-activated proteinkinase and cylooxigenase-2. Hypertension 2003; 421: 1287-1293.
  40. Zalba G., Jose G., Moreno M. et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38: 1395-1399.
  41. Kang D. H., Park S. K., Lee I. K. et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol. 2005;16: 3553-3562.
  42. Hink H. U., Suntanan N., Dikalov S. et al. Peroxidase properties of extracellular superoxid dismutase: role of uric acid in modulating in vivo activity. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1402-1408.
  43. Pittaras A., Kokkinos P., Singh S. et al. Non-dippers have higher incidence of abnormal cardiac structure and function and less favorable lipid, glucose uric acid profile in pre-hypertensive and hypertensive men. J. Hypertens. 2006; 24 (Suppl. 4): S116.
  44. wshima Y., Horio T. Uric acid, left ventricular mass index and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202.
  45. Valerio C., Cuspidi C., Sala С. et al. Lack of association between serum uric acid and organ damage in a never treated essential hypertensive population at low prevalence of hyperuricemia. In: European meeting on hypertension, Milan, June 15-19, 2007: Milan; 2007. P11. 273; S97-S98.

Copyright (c) 2011 Polovitkina O.V., Oshchepkova E.V., Dmitriev V.A., Titov V.N., Polovitkina O.V., Oschepkova E.V., Dmitriev V.A., Titov V.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies